Genmab — April 2012
-
Så kom der endnu et fase 3 forsøg i 3.line CLL mod ofatumumab: Safety and Efficacy of Dinaciclib or Ofatumumab in Participants With Refractory Chronic Lymphocytic Leukemia (P07714)
This study is not yet open for participant recruitment.
Verified April 2012 by Schering-Plough -
hvad har schering ploug at gøre med det?
-
-
Du har ret det er Merck, men de fusionerede med Schering-Plough i 2009. Schering-Plough står som sponsor for studiet. pudsigt
-
Arzerra salgstal i dag... Gæt: 25mill royalty.
-
plejer at være ved 13-tiden
-
de har ligget omkring 20mill de seneste kvartaler. 25 er ikke meget hvis man brænder 500mill om året
-
omkring 12-13 tiden
-
det bliver spændende.
-
det kan vi da håbe på
-
ser ihvertfald frem til at blive klogere idag
-
ja det er jo lige det. Lad os se hvad de leverer til os idag
-
nej desværre. Jeg har alt for travlt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind